We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

iCAD

Offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid an... read more Featured Products: More products

Events

28 Jan 2019 - 01 Feb 2019

Study Demonstrates Advantages of AI for Digital Breast Tomosynthesis

By Medimaging International staff writers
Posted on 25 Oct 2018
Print article
Image: A new study claims AI used with 3D mammography offers improvements in clinical performance and reading times (Photo courtesy of iCad).
Image: A new study claims AI used with 3D mammography offers improvements in clinical performance and reading times (Photo courtesy of iCad).
A study of digital breast tomosynthesis (DBT) cancer detection software by iCAD, Inc. (Nashua, NH, USA) has demonstrated unprecedented improvements in clinical performance and reading times, validating the substantial benefits of Artificial Intelligence (AI) when used with three-dimensional (3D) mammography.

iCAD, a provider of cancer detection and therapy solutions, has developed a cancer detection and workflow solution for breast tomosynthesis that delivers critical benefits to both radiologists and their patients. The new technology is trained to detect malignancies and determine the probability of malignant findings, providing radiologists with a “certainty of finding” score for each case and each detected lesion. These scores represent the algorithm’s confidence that the detected soft tissue densities (masses, architectural distortions and asymmetries) and calcifications are malignant.

iCAD’s latest study of its DBT cancer detection software demonstrated significant positive results for clinical performance and workflow efficiency. The findings confirmed that the latest AI software solution to support DBT increased improvements in both reader sensitivity (8% on average) and specificity (6.9% on average). Additionally, when reading tomosynthesis cases with the solution, the study found that the reading times of radiologists were reduced by more than half (52.7% on average).

“As incidence rates of breast cancer continue to rise, we are proud to provide valuable technology that is proven to significantly improve detection rates while reducing unnecessary recalls resulting from false positives. We also understand that radiologists are concerned about the extra workload and long reading times of tomosynthesis cases in everyday practice and we are pleased to have created a meaningful solution to address this problem,” said Jeff Hoffmeister, MD, Vice President and Medical Director at iCAD. “As tomosynthesis moves into the screening arena, our AI software provides important benefits to radiologists, their practices, and their patients.”


Print article
Clear Image Devices
Italray

Channels

Copyright © 2000-2018 Globetech Media. All rights reserved.